Claris Advisors’s DexCom DXCM Stock Holding History

Claris Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5	Closed	-$335	–	376
2024 Q3	$335	Buy	+5	New	+$411	﹤0.01%	791

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Claris Advisors's DXCM Position: Q4 2024 in Review

Claris Advisors sold out of DexCom (DXCM) in Q4 2024, closing a stake of 5 shares — an estimated $335 sold.

Claris Advisors first reported a position in DXCM in Q3 2024 and held it in 1 quarter. The position peaked at $335 in Q3 2024. 950 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

Claris Advisors reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
Claris Advisors sold 5 DexCom shares in Q4 2024, an estimated $335.
Claris Advisors first reported a position in DexCom in Q3 2024 and held it in 1 quarter.
Claris Advisors's DexCom position peaked at $335 in Q3 2024.
950 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.